Schimmer, A.D., O’Brien, S., Kantarjian, H., Brandwein, J., Cheson, B.D., Minden, M.D., Yee, K., Ravandi, F., Giles, F., Schuh, A., Gupta, V., Andreeff, M., Charles Koller, C., Chang, H., Kamel-Reid, S., Berger, M., Viallet, J. and Borthakur, G. (2008) A Phase I study of the panBcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies, Clinical Cancer Research, 14, 8295-8301. doi:10.1158/1078-0432.CCR-08-0999

has been cited by the following article:

• TITLE: Breast cancer: Small molecules targeting apoptosis, a prospective approach to safe scientific success

  AUTHORS: Mpho Choene, Nonkululeko Mthembu, Zodwa Dlamini, Matlou Mokgotho, James Wachira, Lesetja Motadi

  KEYWORDS: Breast Cancer; Apoptosis; p53 and Natural Products

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.3 No.7, November 26, 2012

  ABSTRACT: Breast carcinoma represents the second leading cause of cancer death in developed countries amongst women. Current cytotoxic chemotherapy plays an important role in the management of patients with hormone-insensitive or metastatic breast carcinoma, although most of them ultimately develop recurrences. Therefore, there is a need for novel targets and treatment strategies in patients with advanced breast carcinoma that is refractory to conventional chemotherapy. This paper summarizes current knowledge on breast cancer targets and molecular mechanisms that follows apoptosis induction.